A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2018

At a glance

  • Drugs Atezolizumab (Primary) ; BL 8040 (Primary) ; Carboplatin (Primary) ; Cobimetinib (Primary) ; CPI 444 (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Pemetrexed (Primary) ; RO 6958688 (Primary) ; Tazemetostat (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MORPHEUS; Morpheus Lung
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 29 Nov 2017 Planned number of patients changed from 307 to 292.
    • 14 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top